ArticleBMJ neurology open2026

Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial.

Günter Höglinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.